首页> 外文会议>International Symposium on Blood Transfusion >NEW TREATMENT OPTIONS IN NEONATAL HYPERBILIRUBINAEMIA
【24h】

NEW TREATMENT OPTIONS IN NEONATAL HYPERBILIRUBINAEMIA

机译:新生儿尿布血症新生儿的新治疗选择

获取原文
获取外文期刊封面目录资料

摘要

Jaundice is one of the most common problems encountered in the newborn period. It has been estimated that in the United States over 60% of the 4 million newborns born each year develop clinical jaundice with bilirubin levels greater than 5 mg/dL (86 mumol/L) in the first week of life. Bilirubin encephalopathy, known pathologically as kernicterus for the yellow staining of the subthalmic nuclei (kerns), has been recognized for a long time. The degree to which bilirubin may cause more subtle neurologic abnormalities remains controversial [1]. While clinical jaundice is commonly encountered in the newborn, kernicterus is a rare occurrence. Factors that affect bilirubin toxicity are complex and incompletely understood. These include; the serum albumin concentration and available binding sites on albumin for bilirubin, the integrity of the blood brain barrier and therefore ability for bilirubin to enter the brain, the duration of bilirubin exposure and the type and stage of development of the cells being exposed [2]. The relationship between increasing total serum bilirubin (TSB) levels, particularly greater then 20 mg/dL (344 mumol/L), and the risk of developing kernicterus in infants with Rh haemolytic disease of the newborn (HDN) was observed in the late 1940s and early 1950s [3]. This led to an aggressive approach to the treatment of jaundice in these patients with exchange transfusion being the predominant mode of therapy to maintain bilirubin levels below 20 mg/dL (344 mumol/L). In 1958 it was observed that premature infants exposed to sunlight or blue fluorescent light experienced a decrease in TSB levels [4]. This prompted the recognition of the possible use of phototherapy as adjunct therapy to exchange. The use of phototherapy as part of the management of hyperbilirubinaemia for infants has remained a standard of care for the past four decades. The use of more effective phototherapy over time has significantly decreased the need for exchange transfusions [5].
机译:黄疸是新生儿时期遇到的最常见问题之一。据估计,在美国在每年出生的400万新生儿中有超过60%的新生儿,在生命的第一周中,胆红素水平大于5 mg / dl(86 mumol / L)的临床黄疸。胆红素脑病,以脑核核(kerns)的黄色染色而被众所周知的脑脑病变已经得到了很长时间的认可。胆红素可能引起更微妙的神经系统异常的程度仍存在争议[1]。虽然临床黄疸通常在新生儿中遇到,而Kernicterus是一种罕见的事件。影响胆红素毒性的因素是复杂和不完全理解的。这些包括;血清白蛋白浓度和可用的胆红素中白蛋白的结合位点,血脑屏障的完整性以及胆红素进入大脑的能力,胆红素暴露的持续时间和曝光细胞的发育的类型和阶段[2] 。在20世纪40年代后期观察到增加总血清胆红素(TSB)水平,特别大于20mg / dl(344mumol / L)的婴儿中婴儿患有Rh溶血(HDN)的婴儿婴儿的风险和20世纪50年代初[3]。这导致了对这些患者治疗黄疸的侵略性的方法,其交换输血是维持胆红素水平以下20mg / dl(344mumol / L)的主要疗法模式。 1958年观察到,暴露于阳光或蓝色荧光灯的早产儿经历了TSB水平的降低[4]。这促使识别可能使用光疗作为交换的辅助疗法。使用光疗法作为婴儿的高胆管血清血症管理的一部分,过去四十年仍然是一种护理标准。随着时间的推移使用更有效的光疗法显着降低了交换输血的需要[5]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号